Abstract-In this paper, we present 8 mathematical model describing the angiogenic response of endothelial cells to a secondary tumour. It. has been observed experimentally that while the primary tumour remains in situ, any secondary tumours that may be present. elsewhere in the host can go undetected, whereas removal of the primary tumour often leads to the sudden appearance of these hitherto undetected metastsses-so-called occult metastases. In this paper, a possible explanation for this suppression of secondary tumours by the primary tumour is given in terms of the presumed migratory response of endothelial cells in the neighbourhood of the secondary tumour. Our model assumes that the endothelial cells respond chemotactically to two opposing chemical gradients: a gradient of tumour angiogenic factor, set up by the secretion of angiogenic cytokines from the secondary tumour; and a gradient of angiostatin, set up in the tissue surrounding any nearby vessels. The angiostatin arrives there through the blood system (circulation), having been originally secreted by the primary tumour. This gradient-driven endothelial cell migration therefore provides a possible explanation of how secondary tumours (occult metastsses) can remain undetected in the presence of the primary tumour yet suddenly appear upon surgical removal of the primary tumour. @J
INTRODUCTION
Solid tumours surmount their dormant avascular state by initiating the formation of new blood vessels from any nearby preexisting vasculature. This development of new blood vessels is known as angiogenesis and is now known to be a crucial step in the metastatic cascade [l] . To start this process, a tumour secretes various chemicals or cytokines, called tumour angiogenic fattors (TAFs) [2] , into the surrounding tissue or extracellular matrix (ECM). As a consequence, endothelial cells (endothelial cell) lining any neighbouring blood vessels are stimulated into a well-ordered sequence of events beginning with the degradation of their basement membrane. Any metsstases which are to grow and survive must undergo precisely the same evolutionary-growth process as the primary tumour, and therefore, at some point in their development will attempt to provoke an angiogenic response in their surrounding tissue to supply the essential nutrients they need to grow and survive. However, found that the primary tumour also produces substances that inhibit angiogenesis, so-called antiangiogenic factors. Given that the primary tumour is fully vascularised, these antiangiogenic factors may flood into the blood stream, and therefore, may inhibit the formation of a vasculature around the secondary tumours. Figure 1 gives a schematic diagram of this process. Without their own vasculature, the metastases remain in a dormant state. Further experimental evidence for this has been observed in animal experiments [7, 8] . In these experiments, several types of tumour were implanted subcutaneously in mice and allowed to grow. The mice were then examined for the presence of secondary tumours, in particular in the lungs. These results showed little or no evidence for the presence of secondary tumours.
However, upon removal of the primary tumour, rapid growth of the hitherto unseen (occult) micrometastases was observed, leading to the growth of many large secondary tumours [8] . ( 1) where n(z,t) is the endothelial cell tip density, D, the cell random motility coefficient, x(c) and o(a) are the TAF chemotactic and angiostatin chemotactic functions, respectively, with c(s,t) and a(z,t) representing the TAF and angiostatin concentrations in the one-dimensional do-
We assume that the blood vessel is located at z = 0 and that the secondary tumour is located at z = L, with host tissue (extracellular matrix) in between.
We assume that the chemotactic function x(c) takes the same form as in (12,151, i.e., we shall assume that endothelial cell receptors become desensitised to high concentrations of TAF, and therefore. take
where xs and Ici are positive constants representing the maximum chemotactic response and the severity of the desensitisation of endothelial cell to TAF, respectively. To model the dose dependent response of endothelial cells to angiostatin, we assume the following simple linear functional form for a(a):
where (ua is a positive constant representing the strength of the chemotactic response to angiostatin. Thus, an increase in the angiostatin concentration (as the primary tumour grows larger) will mean an increased chemotactic response from the endothelial cells. Finally, we note that since the mathematical model is considered in one space dimension only, we omit any interactions between the cells and the ECM. These interactions can be modelled more accurately in two and three space dimensions (see [15] for more information).
To model the TAF and angiostatin concentration distributions in the domain we use simple reaction-diffusion models. We assume that the TAF is produced by the secondary tumour (located at x = L) and simply diffuses and decays. There will also be some loss of TAF through uptake by the endothelial cells or via sequestering by the extracellular matrix. The angiostatin is produced by the primary tumour, is assumed to be transported through the blood system, and then reaches the parent capillary vessel (located at z = 0), where it diffuses into the tissue around the secondary tumour and decays. Once again, there may be some other loss of the chemical as for the TAF.
The two equations governing the distribution of the two chemicals concentrations are, therefore given by
where F and G are functions modelling the uptake/loss and production of the two chemicals. Although the precise functional forms of F and G are unknown, it is expected that any uptake of either chemical can be modelled in a relatively simple manner.
For example, previous work [20] has modelled TAF uptake by endothelial cells using Michaelis-Menten kinetics leading to an uptake term of the form cn/(l +c) while other work [15] has modelled this using an even simpler uptake function nc. For the purposes of this paper, and in particular, in order to carry out some mathematical analysis, the precise functional forms of F and G are, unimportant (we discuss this in more detail later in this section).
As stated previously, the secondary tumour is located at z = L and we assume that the cancer cells produce and secrete TAF at a rate which enables the TAF concentration here to be kept at a constant value co. The TAF diffuses across the domain and reaches x = 0 but does not penetrate the parent vessel. The TAF is therefore assumed to satisfy the following boundary conditions: c = co, z = L; c2 = 0, 5 =. 0.' Similarly, the parent blood vessel is located at x = 0 and we assume that there is sufficient angiostatin reaching here via the bloodstream which enables it to maintain a constant concentration of a = A. Angiostatin diffuses across the domain, and reaches the secondary tumour at 2 = 1. Hence, we assume that the angiostatin concentration satisfies the following boundary conditions:' a = A, z = 0; a, = 0, x = L. We note that the concentration of angiostatin at the parent vessel A may va.ry depending on the size of the primary tumour. Therefore, a high value of A represents a large,primary,tumour and a low value of A represents a small primary tumour. We now nondimensionalise ( 1) , (4), (5) by resealing distance with the parent vessel to secondary tumour distance of L, time with r = L2/D, (where D, is the TAF diffusion coefficient), endothelial cell density with no, and TAF and angiostatin concentration with co and as, respectively (where ca is the TAF concentration at the tumour and ns,as are appropriate reference variables). Therefore, setting and dropping the tildes for clarity, we obtain the nondimensional system, for our simulations, we take D, = 2.9 x 10e7 cm2 s-i. We assume that the diffusion coefficient of angiogstatin is of comparable magnitude. It is known from experimental evidence that the decay of TAF is faster than that of angiostatin (experimental observations concerning the half-life for each chemical [l] ) and so estimates for the parameters yi, 72 may be made using these values. The half-life of angiostatin in the circulation has been estimated at a few hours (-4-6 hours) and the half-life of VEGF in the circulation (a well-known TAF) has been estimated at a few minutes (-3 minutes) [8] . Fr om these estimates, it is clear that TAF decays more rapidly that angiostatin. In Table 1 , we summarise the parameters we have been able to estimate from available experimental data. parameters Xi and X2 from the half-life data and then combining these with r yields values for yi and 72 of around 100 and 5, respectively. We summarise the values of the nondimensional parameters used in the subsequent numerical simulations in Table 2 .
We impose no-flux boundary conditions on the endothelial cells, that is, 
where s = Alao.
Since the diffusion timescale associated with the two chemicals is much faster than that of the cells, we can assume that the chemicals are in a steady-state with respect to the cells, and therefore, satisfy the following equations:
satisfying c(1) = 1, c'(0) = 0, and
satisfying a(0) = s, a'( 1) = 0. In theory, knowing f,g explicitly, we may be able to solve (12) and (13) for C(X) and a(z), and then use these solutions to solve only one equation, namely (6). However, even if functions f and g are known exactly, it may not be possible to do this. In the simple case where we assume no other loss or uptake of the chemicals apart from simple decay, one can easily show that the closed-form solutions to 
Finally, we close the system for the endothelial cells by imposing appropriate initial conditions. With the secondary tumour located at x = 1 and the parent vessel (source of the angiostatin via the primary tumour) of the endothelial cells located at z = 0, we take n(x, 0) = p2/v3J5), O<z<l,
as the initial distribution of endothelial cells. This simple form is chosen to model the fact that endothelial cells in the initial capillary sprouts are located close to the parent vessel. In this section, we analyse our model both analytically and numerically. Since we are interested in whether or not the tumour becomes vascularised, i.e., whether or not endothelial cells at the tips of the capillaries connect with the tumour after some period of time, it is appropriate to examine the steady-state behaviour of our model. Therefore, we now examine the steady-state solutions of (6) with boundary conditions (9).
ANALYTICAL AND NUMERICAL OF THE MODEL
Setting at * = 0 and integrating (6) with respect to x gives
Applying the boundary conditions (9) gives Ei = 0, and hence, Integrating (19) then yields the steady-state solution
where Ez is a constant of integration chosen to ensure conservation of endothelial cell density. Since both terms within the exponential function of (20) are always positive, the steady-state solution will depend upon which of these terms is larger, i.e., if the primary tumour is larger then more angiostatin is produced and the term (crs/2D)[a(s)]" will dominate. Given the functional form of u(z) (cf. (22)), all the endothelial cells will be held (via chemotaxis) close to the parent vessel at II: = 0. The reverse is true if the primary tumour is small (or the secondary is larger). In this case, the term (xs/D~) In (1 + KC(X)) will dominate the solution and so the endothelial cells will migrate (via chemotaxis) to the tumour at J: = 1, thus, completing vascularisation. Clearly, these results are dependent upon the relative sizes of xc, K, and 00.
In order to investigate the model further, both analytically and numerically, we must consider explicit functional forms for a(z) and c(z). However, since the precise functional forms of f and g are unknown, we make the simplifying assumption that the steady-state profiles of TAF and angiostatin are qualitatively similar to those of (16) and (17), i.e., the steady-state TAF concentration profile is a monotonic increasing function on z E [0, l] and the steady-state angiostatin concentration profile is a monotonic decreasing function on x E [0, l]. We therefore take and C(X) = e-(i-z)2/az, 0 5 5 2 1,
o(x) = KZ2+ O<a:Il,
where ~2 and ~1 are both small positive constants with ~2 < ~1. This models the faster decay of TAF compared with angiostatin. The parameter s is a positive constant directly proportional to the size of the primary tumour. As discussed in the introduction, angiostatin is produced by the primary tumour and then flows through the circulation to a vessel close to the secondary tumour. It is known that the inhibitory effect of the primary tumour upon a secondary tumour is directly proportional to the size of the primary [S], thus, the amount of angiostatin produced depends on the size of the primary tumour. Plots of (18), (21), (22) are given in Figure 2 , for ~1 = 0.6, ez = 0.2, and s = 1.0,1.404,1.6. Clearly as s increases, the concentration of angiostatin increases through the whole domain. To examine the effect of primary tumour size upon the angiogenic response to a secondary tumour, we considered the solution profiles of (20) using the TAF and angiostatin profiles (21) and (22) for three different sizes of primary tumour (under the assumption that tumour size is directly proportional to the amount of angiostatin produced). We considered a large tumour (s = 1.6), a medium-sized tumour (s = 1.404), and small tumour (s = 1 .O) (see Figure 2 for how the concentration profiles of angiostatin change with these different parameters). The values of s were chosen to illustrate the range of behaviour our model can produce. Other values of s work equally well, e.g., from our investigations, we found that s 1 1.6 gives no vascularisation, s 5 1.0 gives complete vascularisation and 1.0 < s < 1.6 produces weak vascularisation.
To verify the steady-state results we solved equation (6) numerically using the NAG routine DOSPCF. Taking the same parameter values used for Figure 3 and the boundary and initial conditions given by (9), (18)- (21), we produced Figure 4 . The numerical steady states for s = 1.0, s = 1.404, and s = 1.6 match the analytical solutions closely, thus, verifying the analytical results.
In addition to the above steady-state analysis and numerical simulations, further investigations were carried out which we report here. We examined the solution for'n from (20) using the steadystate profiles for C(X) and a(~) given by (16) and (17) and found qualitatively similar results to those of Figure 3 . Finally, we also carried out numerical simulations on the full time-dependent equations (6)-(B) with explicit uptake functions f = ,&nc and g = /3zna. Once again, we found As shown experimentally, removal of the primary tumour leads to vascularisation of secondaries and subsequent growth [8] . In order to model this behaviour, we mathematically remove the primary tumour. In this case, angiostatin is no longer in steady state, and hence, we consider a time-dependent equation for angiostatin, i.e.,
satisfying 2 = 0 at x = 0,l. The boundary condition at x = 0 now reflects the fact that there is no source of angiostatin, i.e., there is no primary tumour since this has been removed. We now solve equations (6), (7), and (21) Subsequently, the vascularised secondary tumour will grow rapidly as observe&experimentally. . Profiles of the endothelial cell dekity at times t = 0, 1,4,10 in the case where the primary tumour is removed. In this case, the angiostatin decays, the gradient of angiostatin therefore tends to zero thus enabling the endothelial ceils to migrate to the tumour and complete vascularisation. In our model, a value of s > 1 will result in either weak or no vascularization. As we have shown above in Figure 5 , removal of the primary leads to a loss of the angiostatin (perturbing the equilibrium) and subsequent vascularization.
CONCLUSIONS AND DISCUSSION
We have presented a simple mathematical model which describes the control of secondary tumour growth via the primary tumour in a novel manner.
The model' extends and develops previous models of antiangiogenesis (17, 181 These results are based on the assumption that the secondary tumour is close enough to the parent vessel for initiation of angiogenesis to occur. This means that, in the absence of antiangiogeneic factors, vascularization of the secondary tumour will always occur. In wiz~o, of course, it is expected that there will be some secondary tumours which remain avascular (i.e., are not vascularised) even after removal of the primary tumour. Our model could account for this if we located the secondary tumour further from the parent vessel or if the decay rate of TAF was increased.
By extending the model to two or three dimensions, we could include explicit interactions between the EC and the ECM [15] . However, this would not qualitatively change the above results although the rate of capillary growth may be slowed, in line with the results of Anderson and Chaplain [15] . We would also be able to obtain a more detailed description of the resulting capillary network with a discrete form of the model, including the number of branches and anastomoses [12, 15] . Such a discrete model allows for the tracking of individual EC and could therefore be use to explicitly investigate the effect of antiangiogenic drugs upon EC proliferation (see [15] for a more detailed discussion on the discrete modelling of angiogenesis).
Finally, when developing our model, we assumed that endothelial cells respond chemotactically to angiogenic inhibitors (e.g., angiostatin and endostatin). This hypothesis could be proved experimentally but, to our knowledge, such experiments have not yet been conducted.
